Gossamer Bio
A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.
About
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Seralutinib is an inhaled inhibitor designed to enhance the lives of people living with these rare diseases. The company is committed to advancing new therapies and supporting patient communities. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does Gossamer Bio do?
Gossamer Bio is a Biotechnology company that offers Services. Teams look it up for Pharmaceuticals, Healthcare, Biotech. It is based in San Diego, California, USA and was founded in 2017. It was formerly known as []. Public records show about 154 people and $150M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Gossamer Bio raised?
Gossamer Bio has raised a total of $150M in funding. The most recent round on record is Series B.
Where is Gossamer Bio headquartered?
Gossamer Bio is headquartered in San Diego, California, USA.
When was Gossamer Bio founded?
Gossamer Bio was founded in 2017.
What industry does Gossamer Bio operate in?
Gossamer Bio operates in Biotechnology, Pharmaceuticals, Healthcare, Biotech, MedTech.
How many employees does Gossamer Bio have?
Gossamer Bio has approximately 154 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.